Abstract
It was demonstrated that DTPA (diethylenetriaminepentaacetic acid) enhanced the vascular permeability by the intradermal injection test in rats. This change was inhibited by the pretreatment of Epinephrine (vasoconstrictor). The enhancement of vascular permeability was also observed in the small intestinal tract when DTPA was injected intravenously and introduced into the gastro-intestinal tract of rats.
As a result, it was considered that the enhancement of vascular permeability could induce side effects such as the decrease of blood pressure, vasodilation, hemorrhage or congestion in various organs after DTPA administration. Therefore, it was suggested that DTPA should be cautiously treated to humans.
